David Schade
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1154337756
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,450 of the $15,870 with a category attached, or 91.1%. 6 manufacturers reported payments, led by Boehringer Ingelheim at 52.4% of the total. Reporting peaked in 2020 at $7,960 and has fallen 99.5% since, to $36 in 2024. Among endocrinology, diabetes & metabolism clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $991.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- HRA Pharma$7K
- Radius Health, Inc.$122
- Abbott$44
- Merck$36
- Travere Therapeutics, Inc.$1
Across 7 payments — averaging $8789.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$62K
What the payments were for
- Consulting fees$14,45091%
- Travel & lodging$1,0286%
- Food & beverage$3552%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $8,317 |
| HRA Pharma | 1 | $7,350 |
| Radius Health, Inc. | 1 | $122 |
| Abbott | 2 | $44 |
| Merck | 2 | $36 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,870 in reported general payments places this provider in the 90th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 14 | $16,567 |
| Repatha SyringeEvolocumab | 11 | $7,179 |
| Ezetimibe | 159 | $2,944 |
| Rosuvastatin Calcium | 152 | $2,379 |
| HumalogInsulin Lispro | 11 | $1,587 |
| Metformin Hcl ErMetformin Hcl | 28 | $411 |
| Levothyroxine Sodium | 26 | $336 |
| Amlodipine Besylate | 21 | $114 |
| Lisinopril | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
- Lisa EreifejAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.